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Abstract
Background: Conventional total hip replacement (THR) may be felt to carry too high a risk of
failure over a patient's lifetime, especially in young people. There is increasing interest in metal on
metal hip resurfacing arthroplasty (MoM) as this offers a bone-conserving option for treating those
patients who are not considered eligible for THR. We aim to evaluate the effectiveness of MoM for
treatment of hip disease, and compare it with alternative treatments for hip disease offered within
the UK.
Methods: A systematic review was carried out to identify the relevant literature on MoM
published before 2002. As watchful waiting and total hip replacement are alternative methods
commonly used to alleviate the symptoms of degenerative joint disease of the hip, we compared
MoM with these.
Results: The data on the effectiveness of MoM are scarce, as it is a relatively new technique and
at present only short-term results are available.
Conclusion: It is not possible to make any firm conclusions about the effectiveness of MoM based
on these early results. While the short-term results are promising, it is unclear if such results would
be replicated in more rigorous studies, and what the long-term performance might be. Further
research is needed which ideally should involve long-term randomised comparisons of MoM with
alternative approaches to the clinical management of hip disease.
Background
The treatment of younger people with disease of the hip
joint presents a difficult clinical problem. Conventional
total hip replacement (THR) may be felt to carry too high
a risk of failure over a patient's lifetime. Overall, long-
term results of THR in younger patients with a variety of
underlying conditions indicate that 25–30% may require
revision by 15 years [1], compared with less than five per-
cent at ten years for older patients, and less than ten per-
cent at ten or more years for all patients [2]. Specific
subgroups of young active patients, such as those with
osteoarthritis, may experience a revision rate of 50% [3].
In 1999/00 in the NHS in England 18% (8,389) of THRs
were performed on people aged between 15 and 59, 46%
Published: 27 December 2004
BMC Health Services Research 2004, 4:39 doi:10.1186/1472-6963-4-39
Received: 30 January 2004
Accepted: 27 December 2004
This article is available from: http://www.biomedcentral.com/1472-6963/4/39
© 2004 Wyness et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Health Services Research 2004, 4:39 http://www.biomedcentral.com/1472-6963/4/39(21,440) in people aged 60 to 74, and 36% (27,965) in
people aged 75 and over [4]. Data on the number of revi-
sions performed was not so readily available. A previous
report suggested that out of approximately 2700 THRs per
year, 2100 (78%) are primary THRs and 600 (22%) are
revisions [5]. More recent data on revisions of THRs as a
percentage of the total number of THR procedures suggest
that in 1998/99 over ten percent of all THRs were carried
out as revisions [6]. Due to concerns about the risks of
revision, people who are expected to outlive a primary
THR are often managed with non-surgical interventions,
such medication to alleviate pain and to delay or prevent
the need for surgery; collectively these interventions have
been referred to as 'watchful waiting' (WW). People are
typically referred for surgery only when their symptoms
(e.g. pain, loss of physical function) become unmanagea-
ble by non-surgical means. Figures for the number of peo-
ple who have their symptoms managed by pain control
and other non-surgical interventions (such as the use of
transcutaneous electrical nerve therapy and strengthening
exercises) within England and Wales are difficult to deter-
mine. Evidence from a population survey suggest that
15.2 people per 1000 aged 35 to 85 years had hip disease
severe enough for surgery. This equates to approximately
760,000 people within England and Wales [7].
Metal on metal hip resurfacing arthroplasty (MoM) offers
a bone-conserving option for treating those patients who
are not considered eligible for THR. MoM may also repre-
sent a more attractive alternative to other procedures such
as osteotomy, bone fusion and arthroscopy, which have
previously been used or been advocated as means of
delaying or preventing the need for a THR. MoM involves
the removal and replacement of the surface of the femoral
head with a hollow metal hemisphere, which fits into a
metal acetabular cup. This technique conserves femoral
bone (although it is not conservative on the acetabular
side), maintains normal femoral loading and stresses, and
may not therefore compromise future total hip replace-
ments. Data on the use of MoM within the NHS in Eng-
land and Wales could not be obtained in this review.
Never the less, because of increasing interest in MoM, we
conducted a systematic review of the evidence of effective-
ness aiming to compare it with THR and watchful waiting.
Methods
Search strategy
Initial searches failed to identify any randomised or com-
parative observational studies comparing MoM with any
of the chosen alternatives. A structured search was con-
ducted to identify evidence relating to the clinical effec-
tiveness and cost-effectiveness of MoM for treatment of
hip disease. The search strategy comprised of: (1) A free
text search to identify any potentially relevant papers eval-
uating MoM (free text search terms were used because of
the anticipated scarcity of published literature); and (2) A
search for RCTs and systematic reviews of RCTs for THR
using a modified version of the search strategy used for a
recent review [8]. The search strategies used are presented
in the appendix. Appendix [see Additional file 1] The fol-
lowing databases were searched to identify relevant pub-
lished literature: Cochrane database of systematic reviews
(CDSR), Database of abstracts of reviews of effectiveness
(DARE), Cochrane Controlled Trials Register, MEDLINE
and PREMEDLINE, EMBASE, HealthSTAR, CINAHL, NHS
Economic Evaluation Database (EED), and Allied or
Alternative Medicine (AMED). Relevant audit databases
and the World-Wide Web were also searched. Unpub-
lished data sources were sought by contacting experts in
this field and industries with an interest in this area of
orthopaedics. Studies from 1990 to 2001 were searched
for.
Inclusion and exclusion criteria
All identified abstracts were assessed for subject relevance
independently by two reviewers. Full papers were then
obtained and formally assessed for inclusion. It was
agreed at the outset of the review that the search strategy
would not be limited by language. It was agreed that non-
English studies would be identified, but due to time and
resource limitations would not be translated and assessed
for their relevance to the review. No restrictions on the
type of patient were imposed. Comprehensive systematic
reviews of THR was carried out in Health Technology
Assessment in 1998. These reviews were updated by the
National Institute of Clinical Excellence (NICE) in 2000.
Therefore, in this review a search for systematic reviews
and RCTs published subsequent to the completion of the
systematic reviews was carried out. Table 1 describes the
inclusion and exclusion criteria applied for each of the
treatments considered here.
Table 1: Inclusion and exclusion criteria
Treatment Inclusion/Exclusion Criteria
Metal on metal hip resurfacing A minimum of two years follow-up was applied; Studies not reporting the specified outcomes (ref. table 2) 
such as laboratory only studies were excluded.
Watchful waiting Observational data of people receiving WW with a follow-up of greater than five years were included
Total hip replacement RCTs or systematic reviews of RCTs with a minimum of five years follow-up of different methods of THR 
and systematic reviews of such trialsPage 2 of 8
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Timescale Outcomes
Short term Duration of operation
Serious complications (e.g. nerve palsy, haematoma dislocation, infection, re-operation within 6 months
Time in hospital
Time to return to "normal activities" prior to operation
Long term Revision rate
Time to revision surgery
Functional result
Percentage of patients pain free
Quality of life (any recognised generic or condition specific measure e.g. SF-36)
Mortality
Table 3: The number of studies identified for different treatments
Number of studies
Assessment Item Yes No Unable to judge Not applicable
Clarity of study question and definition of outcome
Is the purpose of the study clearly stated? 8 1 1 -
Is the definition of prosthesis failure clear? 7 2 - 1
Is there a clear definition of primary outcome(s)? 7 3 - -
Are standardised outcome measures used? 9 - 1 -
Are the outcome measures used appropriate for the purpose of the study? 9 1 - -
Description of prosthesis and method of fixation
Is the prosthesis design adequately described? 7 2 - 1
Is the method of fixation adequately described? 7 2 - 1
Description of study sample
Is the method of selection of the sample adequately described? 2 7 1 -
Are the study exclusion and inclusion criteria stated? 2 7 1 -
Is the baseline sample clearly described in terms of basic characteristics 
(age, sex etc)?
6 3 1 -
Is the study sample sufficiently homogenous in terms of disease/diagnosis? 5 1 4 -
Is the study sample sufficiently homogenous in terms of co-morbidity? 2 - 8 -
Control of bias in study design
Is the method of randomisation adequate? - - 1 9
Is the method of masking the patient to the intervention allocated stated? - 2 1 7
Were outcome assessors blind to intervention allocation? - 1 3 6
Are baseline values for groups compared? - 1 1 8
Has the study adequately controlled for confounding factors? 1 7 2 -
Duration and completeness of follow-up
Are intervals between surgery and follow-up assessment clearly stated? 8 2 - -
Are reasons for loss of patients at follow-up stated? 2 2 2 4
Are those lost to follow-up compared to the rest of the sample? 1 2 3 4
Is there an appropriate length of follow-up? 8 2 - -
Is the length of follow-up at least 5 years? 3 7 - -
Statistical and analytical considerations
Has the study sample size been justified? - 9 1 -
Are the data clearly presented? 8 2 - -
Was the data analyst masked to interventions? - 5 3 2
Has type of statistical test and actual probability value been stated? 2 1 1 6
Are statistical tests appropriate to study? 2 - 2 6
Is the sample on which failures are assessed adequate? - 2 7 1
Are conclusions justified by evidence? 5 1 3 1Page 3 of 8
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Two reviewers independently abstracted data and quality
assessed the included studies. Where a difference in opin-
ion occurred, an arbiter was consulted. A data abstraction
form was developed to record details of trial methods,
participants, interventions, patient's characteristics and
pre-specified outcomes (See Table 2). The quality assess-
ment form was based on a checklist developed by Morris,
1988 [2] to assess the quality of studies appearing in
orthopaedic research journals.
Results
The initial search identified 352 potentially relevant MoM
studies, 699 potentially relevant THR studies and 177
potentially relevant watchful studies. After reviewing titles
and abstracts and applying the inclusion and exclusion
criteria, data were abstracted from four published MoM
studies [9-12], four published THR studies [2,8,13,14]
and one watchful waiting study [15-17]. Four unpub-
lished studies were also included [18-21]. These were
obtained from companies that manufacture alternative
MoM devices and also through personal communication
with the Robert Jones and Agnes Hunt Orthopaedic and
District Hospital.))No comparative studies were found.
Quality of studies
The majority of studies rated poorly in terms of descrip-
tion of study sample, control of bias, and statistical and
analytical considerations. Most studies rated favourably in
terms of clarity of the study question and definition of
outcome, although less favourably with respect to the
description of the intervention. The duration and com-
pleteness of follow-up was of variable quality, in terms of
the interval between surgery and follow-up being clearly
stated and the consideration of patients lost to follow-up.
Of the three systematic reviews included, two were of high
quality [2,13], although there were some limitations on
the comprehensiveness of the literature searches. The
other systematic review was of lower quality with poor
reporting of the methodology [8]. A summary of the qual-
ity assessment of the remaining ten included studies is
presented in Table 3.
Relative effectiveness of metal on metal hip resurfacing 
arthroplasty
Metal on metal hip resurfacing arthroplasty included studies
The MoM studies included in the review were four pub-
lished studies, three unpublished reports from the manu-
factures of MoM prostheses, and one unpublished report.
(Refer to table 4) The length of follow-up was less than
five years for all the studies and ranging from 8.3 months
[10] to 48 months [20]. The majority of the studies were
small, (4424 [20] to four patients [11]). There was wide
variation of patients' pre-operative diagnoses.
Metal on metal hip resurfacing arthroplasty study outcomes
Only one study reported details on the duration of the
operation [11]. The mean operation time was reported as
247 minutes (range 180 to 370 minutes). McMinn et al,
1996 [10], reported that all patients were mobilised on
the first post-operative day and at 12 days post-operation
all patients had partial weight bearing of 25 kg on the sur-
gically treated leg, with this weight being increased after
12 weeks. Patients in one study [12] spent a median of 21
days in hospital. All except one of the MoM studies
reported the revision rates to THR. They ranged from 0%
to 14.3%. Two groups of patients in the McMinn et al,
1996 [17] study were reported to have no revision to THR.
Details on patients who were pain free were reported in
one published study [17]. In this study 91% (60/66
patients) were pain free after a mean follow-up of 50.2
months (range 44 to 54 months). One of the
manufacturers of MoM prostheses reported 71.1% (69/97
patients) to be pain free after a mean follow-up of 16.9
months [18].
The studies reported few complications. In one study [11]
10.5% (2/19 patients) were reported to have complica-
tions, one a femoral nerve palsy and one a haematoma.
McMinn et al, 1996 [10] reported out of 235 patients,
three patients had infections and one patient had sciatic
nerve palsy. The only complication reported by Wagner et
al, 1996 [12] (a study of 35 patients), was one patient with
a femoral neck fracture, which was due to a traffic acci-
dent. The Oswestry Outcome Centre [20] reported the
majority of revision surgery was due to fractures (56%),
followed by loosening (19%), infection (11%), avascular
necrosis (11%) and dislocation (3%). One manufacturer
reported 6.4% (7/110 patients) to have complications
[18]. Another manufacturer reported 3% (3/100 patients)
to have complications [19]. The most common type of
complication in these two studies was loosening.
Alternative treatments to MoM
Only one watchful waiting study was included in this
review. (Refer to table 5) The results of the study were
reported in two papers, one with results up to three years
[16] and the other up to eight years [17]. All the patients
included in the study suffered from osteoarthritis of the
hip. The study reported that the THR surgery performed
increased from 9 patients (32%) at 3 years, to 14 patients
(48%) at eight years. The number of patients using walk-
ing aids also increased from 8 patients (29%) at three
years, to 12 patients (41%) at eight years. Patients' level of
pain showed a slight increase from three to eight years.
Three systematic reviews provided the majority of infor-
mation on THR for this review [2,8,13]. One of these
reviews [2] included 11 RCTs (mean sample 168
patients), 18 comparative observational studies includingPage 4 of 8
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[22], and 159 observational studies. The second system-
atic review [13] included 17 RCTs, 61 comparative studies
and 145 observational studies. The third review [8]
included the two systematic reviews mentioned above in
addition to four RCTs, ten prospective comparative obser-
vational studies and Swedish Registry data [22]. One addi-
tional recent RCT [14] not included in the earlier
systematic reviews was found from the search in this
review. (Refer to table 6) The review by Fitzpatrick et al
1998 [2], reported an adjusted revision rate per 100 per-
son years at risk of 0.37(+/- 0.02). Faulkner et al, 1998
[13] reported that cemented designs show good survival
at ten to 15 years. The review by NICE, 2001 [8] reported
Table 4: Metal-on-metal studies included in review.
Study (Study design) Funding source Prostheses Mean 
duration of 
follow up 
(range)
Mean 
patient age 
(range)
Revision Rate (unless 
otherwise stated)
Hip Score Pre-
operation/Post-
operation
Amstutz (2000) [9] Specialist orthopedic 
hospital, USA. (Observational) Not 
reported
Cemented, modified 
McMinn acetabular (7 
Hips)
Conserve Plus (29 
Hips)
22 months 
(NR)
40 years 
(NR)
NR NR
McMinn (1996) [10] 3 Birmingham 
Hospitals, UK. (Observational) Not 
reported
Uncemented, 
Uncoated (70 Hips)
50.2 months 
(44–54)a
48.7 years 
(NR)
8/66 patients = 12.1%
60/66 = 90.9% 
patients pain free
pain 3.1b/5.3
mobility 3.1b/5.3
walking 3.1b/5.3
Uncemented, 
Hydroxyapetite 
coating (6 Hips)
40.2 months 
(38–42)a
0/6 patients = 0% pain 3.0b/5.5
mobility 3.1b/6.0
walking 2.7b/5.7
Cemented acetabular 
(43 Hips)
33.2 months 
(23–38)a
4/39 patients = 10.3% pain 2.9b/5.4
mobility 3.0b/5.4
walking 3.2b/5.4
Cemented acetabular, 
Hydroxyapetite 
coating (116 Hips)
8.3 months 
(1–19)a
0/109 patients = 0% pain 3.0b/5.7
mobility 3.2b/5.7
walking 3.2b/5.7
Schmalzried (1996) [11] Specialist 
orthopedic hospital, USA. 
(Observational) Not reported
Cementless Wagner 
(4 Hips)
Cemented McMinn 
(17 Hips)
16 months 
(10–25)
42 years 
(22–64)a
1/19 patients = 5.3% pain 4c/9
walking 6c/9
function 6c/9
activity 4cd/7
Wagner (1996) [12] Specialist orthopedic 
hospital, Germany. (Observational) Not 
reported
2 Ti pins on cupshell 
(12 Hips)
Press fit version (23 
Hips)
20 months 
(6–54)
36 years 
(15–64)a
5/35 patients = 14.3% 32 (5–51)e
d/94 (72–100)ed
Corin Group Ltd, 2001 [18] 4 UK 
Hospitals, 1 UK clinic, 3 surgeons 
(Industry submission) Corin Group Ltd
Cormet 2000 21.36 monthsf 50.8 years 
(26–69)f
Revision Rate CIC
69/97 = 71.1%f
Patients pain free
NR
Midland Medical Technologies Ltd, 2001 
[19] Hospitals in Birmingham 
Southampton Liverpool and Belgium 
(Industry submission) Midland Medical 
Technologies Ltd
Birmingham Hip 
Resurfacing (1761 
Patients)
NR 49.2 years 
(15–86)
8/1382 hips = 0.6% NR
Wright Cremascoli Ortho Ltd, 2001 [21] 
(Industry submission) Wright Cremascoli
Conserve Plus (100 
Hips)
NR (24–51.6) NR 3/100 hips = 3% NR
Oswestry Outcome Centre Database 
[20] Oswestry Outcome Centre 
(Unpublished observational data) 
Oswestry Outcome Centre
McMinn (1378 Hips)
All consultants (4424 
Hips)
0–4 years
0–4 years
53.1 (NR)
49.2 (NR)
7/1378 = 0.5%
34/4424 = 0.77%
66.2e/98.1e
61.3e/95.9e
a Median (range)
b Charnley hip score
c UCLA hip score
d Results of groups reported together
e Harris hip score
f Data from 97 patients (110 hips);
CIC – Data marked as "Commercial in confidence" in the industry report
NR – Not ReportedPage 5 of 8
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10% or less after ten or more years follow-up. The study
by Sharp et al, 2000 [14] reported a revision rate of 27.5%
at a mean follow-up of 5.2 years. It was also reported in
this study that two out of 91 patients (2.2%) had a dislo-
cation within one year post-operation. No evidence on
the extent or nature of complications was reported in any
of the systematic reviews.
Discussion
Despite extensive searching for relevant studies, the evi-
dence base for making comparisons between MoM and
any of the comparators is limited. Initial searches had
already shown a lack of comparative studies and therefore
the focus of the literature search was on identifying less
methodologically robust studies such as data from case
series. Although such searches are problematic due to lack
of specific indexing terms, an extensive search strategy was
devised to identify as many eligible studies as possible.
The early data pertaining to MoM suggests that MoM has
the potential to be an effective technique for the manage-
ment of hip disease. However, due to the lack of any con-
trolled studies, it is difficult to know how much more or
less effective it is compared to any comparators. The data
available with which to make comparisons is uncon-
trolled and the studies identified have, in many cases, con-
sidered patient populations that are dissimilar in many
ways. Identified studies also did not always use compara-
ble outcomes and had different lengths of follow-up.
The lack of long-term data on MoM makes it difficult to
compare with the other comparators. In particular the fail-
ure rates for some types of THR prosthesis increase signif-
icantly after ten years [2], and it is possible the same could
occur with MoM. It is also unclear whether the success
rates reported for THR could be replicated in younger or
more active populations. Comparisons between MoM
and THR studies are difficult as the MoM studies included
Table 5: Watchful waiting studies
Study (Study Design) Funding 
source
Patient 
Characteristics
Patients pain level 
at baseline
Patients pain level 
at follow-up
Use of walking aids Notes
Dieppe (1997) [16] Single 
orthopedic unit (UK) Follow up: 
Mean (range) 37.6 months (31–
41) (Observational study 
Arthritis and Rheumatism 
Council
N = 84 patients
Mean age (SD): 50 
(12.1)
None = 7%
Mild = 48%
Moderate = 31%
Severe = 10%
None = 4%
Mild = 50%
Moderate = 32%
Severe = 14%
9 patients (32 %) at 
baseline
8 patients (29%) at 3 
year follow up
All patients had 
symptomatic limb 
joint osteoarthritis. 
Surgery performed in 
9 patients (32%)
Dieppe (2000) [17] Single 
orthopedic unit (UK) Follow up: 
Mean (range) NR (36–96) 
(Observational study) Arthritis 
and Rheumatism Council
N = 29 patients
Mean age (SD): 50 
(12.1)
None = 7%
Mild = 48%
Moderate = 31%
Severe = 10%
None = 3%
Mild = 34%
Moderate = 48%
Severe = 14%
12 patients (41%) at 8 
year follow up
All patients had 
symptomatic limb 
joint osteoarthritis. 
Surgery performed in 
14 patients (48%)
Note: The studies above involve the same population, but have different length of follow up.
NR: Not Reported.
Table 6: Total hip replacement RCTs of 5 years or more duration not included in the systematic reviews [2,8,13].
Study (Study Design) Prostheses Patient 
Characteristics
Mean duration of 
follow up (range)
Revision Ratebc Hip score post-opd
Sharp (2000) [14] 2 Hospitals 
(UK)a (Observational study) No 
funding received
C-Fit uncemented 
with hydroxyapatite 
porous coating of 
components
N = 91 in total for 
both groups
Mean age: <66 years
5.2 years (1 month–
8 yrs)
25/91 = 27.5% score/patients
12–20/35
21–30/13
31–40/12
41–50/1
50–60/2
a: 1 center randomised, 1 center not randomised
b: Revision rate at latest follow-up point & crude survival rate based on all patients
c: Results reported by patient number on entry to trial i.e. intention to treat
d: Oxford Hip Score
NR: Not ReportedPage 6 of 8
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studies. The evidence from the systematic reviews of dif-
ferent methods of THR reported that several prostheses
had revision rates of ten percent or less at ten years or
more [2,13]. Revision rates reported in the MoM studies
ranged from 0% to 14% for up to 5 years follow-up. The
only other outcome that could be compared is the per-
centage of patients who were pain-free at follow-up. This
was reported to be 90.9% at 50.2 months follow-up in
one group of patients in one MoM study [10]. The system-
atic review conducted by Fitzpatrick and colleagues in
1998 report a mean of 84.1% (range 46–100%) of
patients pain-free at a follow-up of 11 years [2].
In the MoM and WW studies, most of the patients had a
preoperative diagnosis of osteoarthritis and were all of a
similar younger age. The watchful waiting study reported
32% of patients requiring surgery at 3 years and 48% by
eight years follow-up [15-17]. In the MoM studies revision
rates ranged from 0% to 14.3%, after a follow-up of less
than five years. During the 8-year follow-up period, peo-
ple managed with WW had a slight increase in their pain
levels, whereas the MoM patients hip scores all improved.
91% (60/66) of MoM patients were pain free after a mean
follow-up of 50.2 months in one study [10], and 71%
(69/97) after a mean follow-up of 16.9 months in the
only other study that reported this outcome [18]. The very
limited evidence available suggests that MoM is more
effective in terms of better quality of life (measured by
pain scores for WW and hip scores for MoM) than WW
over a follow-up of approximately three years.
As the relative effectiveness of MoM is unclear the cost-
effectiveness of MoM is also uncertain. It is likely the MoM
procedure would cost approximately £5,500 whereas a
THR would cost about £4,200 and the annual cost of WW
(including the cost of NSAID (Non steroidal anti-inflam-
matory drugs) therapy, physiotherapy and treatment of
side effects of medications) would be about £640 [23].
Whether MoM proves to be cost-effective against these
alternatives depends upon the rates of revision to THR of
MoM and WW, and the rates of revision of THR. The oper-
ation rates reported from the one WW study [15-17] and
the revision rates of MoM suggest that MoM may provide
better outcome at lower cost over a ten-year period. Such
information remains at best tentative due to the small
number of people to whom the watchful waiting data
relate, the short follow-up of the MoM studies, and the
uncontrolled nature of the comparison.
Conclusions
The use of MoM in the UK is still relatively rare. However,
there has been increasing interest from younger people
with hip disease who are not currently considered eligible
for THR and amongst surgeons who strive for better ways
to treat the patients whom they see. However, only very
limited evidence are currently available on MoM and
although the procedure does appear promising the lack of
robust comparisons with the other treatment options and
of long term data make it virtually impossible to draw
robust conclusions about its relative effectiveness. Given
the early promise shown by MoM there is a real need for
more rigorous research. Such research would be challeng-
ing, not least because of ethical considerations, but
should attempt some form of prospective, preferably ran-
domised, comparison of MoM with a policy of delayed
selective surgery. These studies should preferably be large-
scale, long-term, and use standard outcome measures,
both pre- and post-operatively.
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